Enspryng (satralizumab)


Enspryng is approved in Canada, Japan and Switzerland, as a monotherapy or in combination with baseline immunosuppressant therapy, for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent patients who are aquaporin-4 antibody (AQP4-IgG) seropositive. In the U.S., it is approved for adults living with anti-aquaporin-4 (AQP4) antibody-positive NMOSD.

Enspryng is a monoclonal antibody, administered subcutaneously every four weeks, which targets the interleukin-6 (IL-6) receptor. IL-6 is a signalling protein, produced by immune cells in the body, that is believed to play a key role in the inflammation occurring in people with NMOSD, leading to unpredictable and severe relapses.

Enspryng was designed by Chugai using novel antibody recycling technology, which allows for longer duration of antibody circulation and maximum inhibition of IL-6 signalling, while minimising safety risks in a chronic disease setting.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.